Maria Zannes | Source | CEO, President, and Director at bioAffinity Technologies, Inc.
Maria Zannes
Maria is the Chief Executive Officer, President, and Director at bioAffinity Technologies, Inc. She brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Maria founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental and energy fields. In her current capacity,, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics.
-
bioAffinity Technologies, Inc.
CEO, President, and Director
-
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
bioAffinity Technologies raises the 2024 full-year forecast for sales of CyPath Lung, a noninvasive test for lung cancer, by 85%.
Article
-
We strategically focused our marketing efforts on our home state of Texas as we launched CyPath® Lung, a noninvasive test that has shown 92% sensitivity and 87% specificity in detecting cancer in the lung for people who have pulmonary nodules 20 millimeters or less. The strategic decision to begin our commercial launch in Texas allows us to hone our message, improve operations and prepare for a broader market launch now scheduled for the fourth quarter of 2024.
